Cost-effectiveness of single-inhaler triple therapy for patients with severe COPD: a systematic literature review

References

• Adeloye D, Song P, Zhu Y, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med. 2022;10(5):447–458.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Fact Sheet: chronic obstructive pulmonary disease (COPD). Online: World Health Organization; 2022. https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)
   Google Scholar
• Buist ASP, McBurnie MAP, Vollmer WMP, et al. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet. 2007;370(9589):741–750.
   PubMed Web of Science ®Google Scholar
• Chrystyn H, Small M, Milligan G, et al. Impact of patients’ satisfaction with their inhalers on treatment compliance and health status in COPD. Respir Med. 2014;108(2):358–365.
   PubMed Web of Science ®Google Scholar
• van Boven JF, Chavannes NH, van der Molen T, et al. Clinical and economic impact of non-adherence in COPD: a systematic review. Respir Med. 2014;108(1):103–113.
   PubMed Web of Science ®Google Scholar
• King D, Zhang S, Rosen V, et al. Single versus multiple inhalers in patients with chronic obstructive pulmonary disease (COPD): a systematic literature review. Value Health. 2017;20(9):A574.
   Google Scholar
• Mäkelä MJ, Backer V, Hedegaard M, et al. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med. 2013;107(10):1481–1490.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish COPD guidelines (GesEPOC) 2017. Pharmacological treatment of stable chronic obstructive pulmonary disease. Archivos de Bronconeumología English. 2017;53(6):324–335.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Zhu J, Liu Y, et al. Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis. BMJ. 2018;363:k4388–k4388.
   PubMedGoogle Scholar
• Lipson DA, Barnacle H, Birk R, et al. Reply: “Fulfil an unmet need in chronic obstructive pulmonary disease” and “triple therapy in chronic obstructive pulmonary disease”. Am J Respir Crit Care Med. 2017;196(8):1083–1084.
   PubMedGoogle Scholar
• Ferguson GT, Rabe KF, Martinez FJ. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial (vol 6, pg 747, 2018). Lancet Respir Med. 2019;7(2):E9–E9.
   Web of Science ®Google Scholar
• Mandelbtatt JS, Fryback DG, Weinstein MC, et al. Assessing the effectiveness of health interventions for cost-effectiveness analysis. J Gen Intern Med. 1997;12(9):551–558.
   PubMed Web of Science ®Google Scholar
• Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164. https://doi.org/10.1183/13993003.00164-2019
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582.
   PubMed Web of Science ®Google Scholar
• Syed AA, Sharma GN, Shrivastav B, et al. Meta-analysis of cost-effectiveness of three-drug therapy versus two-drug therapy in chronic obstructive pulmonary disease patients. J Appl Pharm Sci. 2021;11(9);129–138. https://doi.org/10.7324/JAPS.2021.110916 .
   Google Scholar
• Balmaceda C, Espinoza MA, Abbott T, et al. Cost-effectiveness analysis: fluticasone furoate/umeclidinium/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health system. Expert Rev Pharmacoecon Outcomes Res. 2022;6:1–9.
   Google Scholar
• Bogart MR, Hopson SD, Shih H-C, et al. COPD exacerbation costs in the IMPACT study: a within-trial analysis. Am J Manag Care. 2020;26(5):e150–e154.
   PubMed Web of Science ®Google Scholar
• Chen H . Economic Evaluation of Single-Inhaler Triple Therapy (FF/UMEC/VI) for COPD - An explorative cost-effectiveness analysis in a Norwegian perspective (University of Oslo, The Faculty of Medicine,). 2019 Accessed 13 November 2022 https://www.duo.uio.no/bitstream/handle/10852/71743/5/Master-thesis-TripleInhaler-COPD-Hsin-Chen-.pdf.
   Google Scholar
• Driessen M, Shah D, Risebrough N, et al. Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: a UK perspective. Respir Med. 2018;145:130–137.
   PubMed Web of Science ®Google Scholar
• Fenwick E, Martin A, Schroeder M, et al. Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK. ERJ Open Res. 2021 Jan;7(1):00480–2020. https://doi.org/10.1183/23120541.00480-2020.
   PubMedGoogle Scholar
• Ismaila A, Birk R, Shah D, et al. Once-daily triple therapy in patients with advanced COPD: healthcare resource utilization data and associated costs from the fulfil trial. Adv Ther. 2017;34(9):2163–2172.
   PubMed Web of Science ®Google Scholar
• Ismaila A, Risebrough N, Schroeder M, et al. Cost-effectiveness of once-daily single-inhaler triple therapy in COPD: the impact trial. Int J Chron Obstruct Pulmon Dis. 2019;14:2681–2695.
   PubMed Web of Science ®Google Scholar
• Liu J, He X, Wu J. Economic evaluation of triple therapy with budesonide/glycopyrrolate/formoterol fumarate for the treatment of moderate to very severe chronic obstructive pulmonary disease in China using a semi-Markov model. Appl Health Econ Health Policy. 2022 Apr 28;20:743–755. https://doi.org/10.1007/s40258-022-00732-1.
   PubMed Web of Science ®Google Scholar
• Martin A, Shah D, Ndirangu K, et al. Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial. ERJ Open Res. 2022 Jan;8(1):00333–2021. https://doi.org/10.1183/23120541.00333-2021
   PubMedGoogle Scholar
• Miravitlles M, Marín A, Huerta A, et al. Estimation of the clinical and economic impact of an improvement in adherence based on the use of once-daily single-inhaler triple therapy in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:1643–1654.
   PubMed Web of Science ®Google Scholar
• Schroeder M, Shah D, Risebrough N, et al. Cost-effectiveness analysis of a single-inhaler triple therapy for patients with advanced chronic obstructive pulmonary disease (COPD) using the FULFIL trial: a UK perspective. Respiratory Medicine: X. 2019;1:100008 https://doi.org/10.1016/j.yrmex.2019.100008.
   Google Scholar
• Schroeder M, Benjamin N, Atienza L, et al. Cost-effectiveness analysis of a once-daily single-inhaler triple therapy for patients with chronic obstructive pulmonary disease (COPD) using the FULFIL trial: a Spanish perspective. Int J Chron Obstruct Pulmon Dis. 2020;15:1621–1632.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Long E, Xu Q, et al. Cost-effectiveness analysis of triple combination preparations in the treatment of moderate-to-severe chronic obstructive pulmonary disease. Front Public Health. 2021;9:713258.
   PubMed Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.
   PubMed Web of Science ®Google Scholar
• Cost-effectiveness of single-inhaler triple therapy for patients with asthma and chronic obstructive pulmonary disease: a systematic review and meta-analysis. [Internet]. PROSPERO-International prospective register of systematic reviews: National Institute for Health Research. 2021. Available from: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=221840.
   Google Scholar
• Amir-Behghadami M, Janati A. Population, Intervention, Comparison, Outcomes and Study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews. Emerg Med J. 2020 [cited 2022 November 13]. https://doi.org/10.1136/emermed-2020-209567.
   Google Scholar
• van Mastrigt GA, Hiligsmann M, Arts JJ, et al. How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: a five-step approach (part 1/3). Expert Rev Pharmacoecon Outcomes Res. 2016;16(6):689–704.
   PubMed Web of Science ®Google Scholar
• Shemilt I, Thomas J, Morciano M. A web-based tool for adjusting costs to a specific target currency and price year. Evidence & Policy: A J Res Debate Pract. 2010;6(1):51–59.
   Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)—explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231–250.
   PubMed Web of Science ®Google Scholar
• Fatoye F, Wright JM, Gebrye T. Cost-effectiveness of physiotherapeutic interventions for low back pain: a systematic review. Physiotherapy. 2020 [2020 Sep 01];108:98–107.
   PubMed Web of Science ®Google Scholar
• Chiou C-F, Hay JW, Wallace JF, et al. Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care. 2003;41(1):32–44.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease Inc. Online: Global Initiative for Chronic Obstructive Lung Disease. Online: Global Initiative for Chronic Obstructive Lung Disease. 2020 [cited 2022 November 13]. https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf
   Google Scholar
• White P, Thornton H, Pinnock H, et al. Overtreatment of COPD with inhaled corticosteroids-implications for safety and costs: cross-sectional observational study. PloS one. 2013;8(10):e75221.
   PubMed Web of Science ®Google Scholar
• Price D, Brusselle G. Challenges of COPD diagnosis. Expert Opin Med Diagn. 2013;7(6):543–556.
   PubMedGoogle Scholar
• Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease, Cochrane Database Syst Rev, 2014;(3): 1–23. https://doi.org/10.1002/14651858.CD010115.pub2.
   Google Scholar
• Maleki-Yazdi M, Molimard M, Keininger DL, et al. Cost effectiveness of the long-acting β2-adrenergic agonist (LABA)/Long-acting muscarinic antagonist dual bronchodilator indacaterol/glycopyrronium versus the LABA/inhaled corticosteroid combination salmeterol/fluticasone in patients with chronic obstructive pulmonary disease: analyses conducted for Canada, France, Italy, and Portugal. App Heal Econ Heal Pol. 2016;14(5):579–594.
   PubMed Web of Science ®Google Scholar
• López-Campos JL, Carrasco-Hernández L, Román Rodríguez L, et al. The clinical implications of triple therapy in fixed-dose combination in COPD: from the trial to the patient. Arch Bronconeumol. 2020;56(4):242–248.
   PubMed Web of Science ®Google Scholar
• Kwak M-S, Kim E, Jang EJ, et al. The efficacy and safety of triple inhaled treatment in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis using Bayesian methods. Int J Chron Obstruct Pulmon Dis. 2015;10(1):2365–2376.
   PubMedGoogle Scholar
• Eleanor LA, Adam L, James P, et al. Inhaled therapies for chronic obstructive pulmonary disease: a systematic review and meta-analysis. BMJ Open. 2020;10(9):e036455–e036455.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017 [2017 May 13];389(10082):1919–1929.
   PubMed Web of Science ®Google Scholar
• Singh D, Corradi M, Spinola M, et al. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide. Int J COPD. 2017;12:2917.
   Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680.
   PubMed Web of Science ®Google Scholar
• Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963–973.
   PubMed Web of Science ®Google Scholar
• Papi A, Petruzzelli S, Vezzoli S, et al. Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations. Eur Respir J. 2019;53(4):1900147.
   PubMedGoogle Scholar
• Lipworth B, Kuo CR, Jabbal S. Current appraisal of single inhaler triple therapy in COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:3003–3009.
   PubMed Web of Science ®Google Scholar
• Akazawa M, Stempel DA. Single-inhaler combination therapy for asthma a review of cost effectiveness. Pharmacoeconomics. 2006;24(10):971–988.
   PubMed Web of Science ®Google Scholar
• Vanfleteren L, Ullman A, Nordenson A, Lowie, EGW, et al. Triple therapy (ICS/LABA/LAMA) in COPD: thinking out of the box. ERJ Open Res. 2019 Feb;5(1):00185–2018. https://doi.org/10.1183/23120541.00185-2018.
   PubMedGoogle Scholar
• Suissa S, Dell’Aniello S, Ernst P. Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events. Eur Respir J. 2017;49(5):02245–2016. https://doi.org/10.1183/13993003.02245-2016.
   Web of Science ®Google Scholar
• Lexchin J, Bero LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326(7400):1167–1170.
   PubMed Web of Science ®Google Scholar
• Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. Jama. 2003;289(4):454–465.
   PubMed Web of Science ®Google Scholar